{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:30:38Z","timestamp":1787635838791,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,9,3]],"date-time":"2014-09-03T00:00:00Z","timestamp":1409702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,9,3]],"date-time":"2014-09-03T00:00:00Z","timestamp":1409702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s11920-014-0489-1","type":"journal-article","created":{"date-parts":[[2014,9,2]],"date-time":"2014-09-02T06:02:16Z","timestamp":1409637736000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Antagonist Models for Treating Persons With Substance use Disorders"],"prefix":"10.1007","volume":"16","author":[{"given":"George E.","family":"Woody","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,3]]},"reference":[{"issue":"1","key":"489_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1530-0277.2006.00013.x","volume":"30","author":"H Krampe","year":"2006","unstructured":"Krampe H, Stawicki S, Wagner T, Bartels C, Aust C, R\u00fcther E, et al. Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome. Alcohol Clin Exp Res. 2006;30(1):86\u201395. doi:10.1111\/j.1530-0277.2006.00013.x.","journal-title":"Alcohol Clin Exp Res"},{"issue":"11","key":"489_CR2","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1001\/jama.1986.03380110055026","volume":"256","author":"RK Fuller","year":"1986","unstructured":"Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, et al. Disulfiram treatment of alcoholism: a veterans administration cooperative study. JAMA. 1986;256(11):1449\u201355. doi:10.1001\/jama.1986.03380110055026.","journal-title":"JAMA"},{"key":"489_CR3","first-page":"251","volume-title":"Textbook of substance abuse treatment","author":"HD Kleber","year":"1999","unstructured":"Kleber HD. Opioids: detoxification. In: Galanter M, Kleber HD, editors. Textbook of substance abuse treatment. 2nd ed. Washington: American Psychiatric Association; 1999. p. 251\u201369.","edition":"2"},{"key":"489_CR4","first-page":"1207","volume":"29","author":"MC Lee","year":"1998","unstructured":"Lee MC, Wagner HN, Tanada S, Frost JJ, Bice AN, Dannals RF. Duration of occupancy of opiate receptors by naltrexone. J Nucl Med. 1998;29:1207\u201311.","journal-title":"J Nucl Med"},{"key":"489_CR5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jsat.2004.02.002","volume":"26","author":"EM Krupitsky","year":"2004","unstructured":"Krupitsky EM, Zvartau EE, Masalov DV, Tsoi MV, Burakov AM, Egorova VY, et al. Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J Subst Abuse Treat. 2004;26:285\u201394.","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"489_CR6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jsat.2006.05.005","volume":"31","author":"EM Krupitsky","year":"2006","unstructured":"Krupitsky EM, Zvartau EE, Masalov DV, Tsoi MV, Burakov AM, Egorova VY, et al. Naltrexone and fluoxetine for heroin dependence treatment in St. Petersburg, Russia. J Subst Abuse Treat. 2006;31(4):319\u201328.","journal-title":"J Subst Abuse Treat"},{"key":"489_CR7","first-page":"529","volume":"14","author":"JW Cornish","year":"1998","unstructured":"Cornish JW, Metzger D, Woody GE, Wilson D, McLellan AT, Vandergrift B, et al. Naltrexone pharmacotherapy for opioid dependent federal probationers. Drug Alcohol Depend. 1998;14:529\u201334.","journal-title":"Drug Alcohol Depend"},{"key":"489_CR8","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1037\/0022-006X.71.3.432","volume":"71","author":"W Fals-Stewart","year":"2003","unstructured":"Fals-Stewart W, O\u2019Farrell TJ. Behavioral family counseling and naltrexone for male opioid-dependent patients. J Consult Clin Psychol. 2003;71:432\u201342.","journal-title":"J Consult Clin Psychol"},{"key":"489_CR9","doi-asserted-by":"crossref","unstructured":"Hulse GK, Morris N, Arnold-Reed D, Tait RJ. Improving clinical outcomes in treating heroin dependence: randomised, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry. 2009;66:1108\u201315. Australian New Zealand Clinical Trial anzctr.org ACTRN12606000308594.","DOI":"10.1001\/archgenpsychiatry.2009.130"},{"key":"489_CR10","doi-asserted-by":"crossref","unstructured":"Krupitsky EM, Zvartau EE, Blokhina E, Verbitskaya E, Wahlgren V, Tsoy-Podosenin M, et al. Randomized trial of long acting sustained release naltrexone implant vs. oral naltrexone or placebo for preventing relapse to opioid dependence. Arch Gen Psychiatry. 2012;69(9):973\u201381. This double blind, double dummy study compared an implant that contains 1000 mg naltrexone that is slowly released and blocks opioids for 2-3 months (Prodetoxon), with 50 mg\/day oral naltrexone and double placebo. Results showed a strong effect of the implant over the other two conditions with over half of the implant patients staying in treatment and not relapsing by the end of 6 months as compared to 15% of the oral naltrexone group and 10% of the placebo group. Though Prodetoxon is not commercially available in the U.S., results were consistent with other studies showing that extended release naltrexone formulations have the potential to be meaningful additions to current treatment options for opioid addiction.","DOI":"10.1001\/archgenpsychiatry.2012.1a"},{"key":"489_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","volume":"63","author":"SD Comer","year":"2006","unstructured":"Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63:210\u20138.","journal-title":"Arch Gen Psychiatry"},{"key":"489_CR12","doi-asserted-by":"crossref","unstructured":"Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind. placebo-controlled, multicenter randomised trial. Lancet. 2011;377:1506\u201313. Public Access Compliance in process at: NIHMSID.","DOI":"10.1016\/S0140-6736(11)60358-9"},{"key":"489_CR13","doi-asserted-by":"crossref","unstructured":"O\u2019Brien CP, Friedmann PD, Nunes E, Lee JD, Kinlock W. Depot naltrexone as relapse prevention for opiod-dependence parolees. Presented at the 76th Annual Scientific Meeting College on Problems of Drug Dependence, 2014.","DOI":"10.1016\/j.drugalcdep.2014.09.519"},{"issue":"2","key":"489_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMsa064115","volume":"356","author":"IA Binswanger","year":"2007","unstructured":"Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, et al. Release from prison: a high risk of death for former inmates. N Engl J Med. 2007;356(2):157\u201365.","journal-title":"N Engl J Med"},{"issue":"2","key":"489_CR15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1360-0443.2007.02081.x","volume":"103","author":"M Farrell","year":"2007","unstructured":"Farrell M, Marsden J. Acute risk of drug related death among newly released prisoners in England and Wales. Addiction. 2007;103(2):251\u20135.","journal-title":"Addiction"},{"key":"489_CR16","doi-asserted-by":"crossref","unstructured":"Woody GE, Metzger DS. Injectable extended release naltrexone for opioid dependence. Lancet. 2011;378:664\u20135. Letter to Editor.","DOI":"10.1016\/S0140-6736(11)61330-5"},{"key":"489_CR17","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1530-0277.2007.00593.x","volume":"32","author":"MR Lucey","year":"2008","unstructured":"Lucey MR, Silverman BL, Illeperuma A, O'Brien CP. Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics. Alcohol Clin Exp Res. 2008;32:498\u2013504.","journal-title":"Alcohol Clin Exp Res"},{"key":"489_CR18","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1001\/archpsyc.1992.01820110040006","volume":"49","author":"JR Volpicelli","year":"1992","unstructured":"Volpicelli JR, Alterman AI, Hayashida M, O\u2019Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876\u201380.","journal-title":"Arch Gen Psychiatry"},{"key":"489_CR19","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/archpsyc.1992.01820110045007","volume":"49","author":"SS O'Malley","year":"1992","unstructured":"O'Malley SS, Jaffe A, Chang G, Schottenfeld RS, Meyer RE, Rounsaville BJ. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry. 1992;49:881\u20137.","journal-title":"Arch Gen Psychiatry"},{"key":"489_CR20","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1111\/j.1530-0277.1994.tb00098.x","volume":"18","author":"BJ Mason","year":"1994","unstructured":"Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res. 1994;18:1162\u20137.","journal-title":"Alcohol Clin Exp Res"},{"key":"489_CR21","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/archpsyc.56.8.719","volume":"56","author":"BJ Mason","year":"1999","unstructured":"Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry. 1999;56:719\u201324.","journal-title":"Arch Gen Psychiatry"},{"key":"489_CR22","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","volume":"295","author":"RF Anton","year":"2006","unstructured":"Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003\u201317.","journal-title":"JAMA"},{"key":"489_CR23","doi-asserted-by":"crossref","unstructured":"Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013;108:275\u201393. This review provides very important information that might explain the different results from naltrexone and acamprosate for treatment of alcohol dependence in studies that were done in the U.S. and Western Europe.","DOI":"10.1111\/j.1360-0443.2012.04054.x"},{"issue":"6","key":"489_CR24","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/01.jcp.0000144893.29987.e5","volume":"24","author":"N Jayaram-Lindstrom","year":"2004","unstructured":"Jayaram-Lindstrom N, Wenneberg P, Hurd YL, Franck J. Effects of naltrexone on the subjective response to amphetamine in healthy volunteers. J Clin Psychopharmacol. 2004;24(6):665\u20139.","journal-title":"J Clin Psychopharmacol"},{"key":"489_CR25","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/08039480510023052","volume":"29","author":"N Jayaram-Lindstrom","year":"2005","unstructured":"Jayaram-Lindstrom N, Wenneberg P, Beck O, Franck J. An open clinical trial of naltrexone for amphetamine addiction: compliance and tolerability. Nord J Psychiatry. 2005;29:167\u201371.","journal-title":"Nord J Psychiatry"},{"key":"489_CR26","doi-asserted-by":"crossref","unstructured":"Jayaram-Lindstrom N, Konstenius M, Eksborg S, Beck O, Hammarberg A, Franck J. Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine addiction. Neuropsychopharmacology. 2007 (E-pub ahead of print; Oct. 24) doi:10.1038:1-8.","DOI":"10.1038\/sj.npp.1301572"},{"key":"489_CR27","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1176\/appi.ajp.2008.08020304","volume":"165","author":"N Jayaram-Lindstrom","year":"2008","unstructured":"Jayaram-Lindstrom N, Hammarberg A, Beck O, Franck J. Naltrexone for the treatment of amphetamine addiction: a randomized, placebo-controlled trial. Am J Psychiatry. 2008;165:1442\u20138.","journal-title":"Am J Psychiatry"},{"key":"489_CR28","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1176\/appi.ajp.2011.11071121","volume":"169","author":"J Tiihonen","year":"2012","unstructured":"Tiihonen J, Krupitsky E, Verbitskaya E, Blokhina E, Mamontova O, Fohr J, et al. Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial. Am J Psychiatry. 2012;169:531\u201368.","journal-title":"Am J Psychiatry"},{"key":"489_CR29","unstructured":"Woody GE. Emerging data on efficacy and clinical applications of extended release naltrexone; symposium chair, CPDD, 75th Annual Scientific Meeting, NIDA International Forum, June 13-20, 2013 San Diego, CA."},{"issue":"2","key":"489_CR30","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/bcp.12115","volume":"77","author":"T Kosten","year":"2013","unstructured":"Kosten T, Domingo C, Orson F, Kinsey B. Vaccines against stimulants: cocaine and MA. Br J Clin Pharmacol. 2013;77(2):368\u201374. Anti-addiction vaccines have great potential for treating substance use disorders by eliciting an antibody response that blocks drug effects. This paper reviews vaccine-based approaches to treating stimulant addictions with a focus on cocaine, but also presents data related to pre-clinical development of a methamphetamine vaccine and reviews the mechanism of action for vaccine induced antibodies to abused drugs which involves slowing of brain entry as well as simple blocking properties.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"489_CR31","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/clpt.2010.317","volume":"89","author":"DK Hatsukami","year":"2011","unstructured":"Hatsukami DK, Jorenby DE, Gonzales D, Rigotti NA, Glover ED, Oncken CA, et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther. 2011;89(3):392\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"489_CR32","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1586\/erv.13.1","volume":"12","author":"S Brimijoin","year":"2013","unstructured":"Brimijoin S, Shen X, Orson F, Kosten T. Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse. Expert Rev. 2013;12(3):323\u201332. Clinical trials of vaccines against cocaine and nicotine have been completed with the generally encouraging result that subjects showing high titers of anti-drug antibody experience a reduction in drug reward, which may result in decreased use with health benefits. It also discusses new vaccine technologies including gene transfer of monoclonal antibodies.","journal-title":"Expert Rev"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-014-0489-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11920-014-0489-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-014-0489-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-014-0489-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T21:57:30Z","timestamp":1744149450000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11920-014-0489-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,3]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["489"],"URL":"https:\/\/doi.org\/10.1007\/s11920-014-0489-1","relation":{},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,3]]},"assertion":[{"value":"3 September 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"489"}}